{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:39:24Z","timestamp":1792453164395,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1053\/j.ackd.2014.01.007","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T04:01:59Z","timestamp":1393905719000},"page":"121-133","source":"Crossref","is-referenced-by-count":29,"title":["Novel Therapies for Diabetic Kidney Disease"],"prefix":"10.1053","volume":"21","author":[{"given":"Radica Z.","family":"Alicic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"50","key":"10.1053\/j.ackd.2014.01.007_bib1","first-page":"850","article-title":"KDOQI Clinical Practice Guideline for diabetic and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.007_bib2","series-title":"Diabetic Nephropathy","article-title":"The history of diabetic nephropathy","author":"Tattersal","year":"2000"},{"key":"10.1053\/j.ackd.2014.01.007_bib3","series-title":"National Kidney Disease Fact Sheet: General Information and National Estimates on Chronic Kidney Disease in the United States, 2010","author":"Centers for Disease Control and Prevention","year":"2010"},{"key":"10.1053\/j.ackd.2014.01.007_bib4","series-title":"National Center for Chronic Disease Prevention and Health Promotion. Division of Diabetes Translation. Chronic Kidney Disease Initiative","year":"2012"},{"key":"10.1053\/j.ackd.2014.01.007_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.diabres.2011.10.029","article-title":"IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030","volume":"94","author":"Whiting","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.ackd.2014.01.007_bib6","series-title":"National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011","author":"Centers for Disease Control and Prevention","year":"2011"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.007_bib7","first-page":"260","article-title":"Diffuse diabetic glomerulosclerosis in a patient with impaired glucose tolerance: report on a patient who later develops diabetes mellitus","volume":"60","author":"Altiparmak","year":"2002","journal-title":"Neth J Med"},{"issue":"11","key":"10.1053\/j.ackd.2014.01.007_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ncpneph0946","article-title":"Nodular glomerulosclerosis in a patient with metabolic syndrome without diabetes","volume":"4","author":"Souraty","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib9","series-title":"International Diabetes Federation Diabetes Atlas","year":"2011"},{"key":"10.1053\/j.ackd.2014.01.007_bib10","unstructured":"World Health Organization. Fact Sheet No. 311. Available at: http:\/\/www.who.int\/entity\/mediacentre\/factsheets\/fs311\/en\/. Accessed September\u00a030, 2013."},{"key":"10.1053\/j.ackd.2014.01.007_bib11","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","article-title":"Prevalence of overweight and obesity in the United States, 1999\u20132004","volume":"295","author":"Ogden","year":"2006","journal-title":"J Am Med Assoc"},{"issue":"24","key":"10.1053\/j.ackd.2014.01.007_bib12","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"J Am Med Assoc"},{"key":"10.1053\/j.ackd.2014.01.007_bib13","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.ki.5000377","article-title":"Prevalence and risk factors for macroalbuminuria in a referred cohort of type II diabetic patients: a global perspective","volume":"69","author":"Parving","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.007_bib14","series-title":"U.S. Renal Data System. USRDS 2012 Annual Data Report: Disease","year":"2010"},{"key":"10.1053\/j.ackd.2014.01.007_bib15","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1053\/j.ajkd.2008.07.054","article-title":"CKD surveillance using laboratory date from the population-based National Health and Nutrition Examination Survey (NHANES)","volume":"53","author":"Castro","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.007_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2215\/CJN.05070511","article-title":"Risks of subsequent hospitalization and death in patients with kidney disease","volume":"7","author":"Daratha","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib18","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0140-6736(82)92450-3","article-title":"Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus","volume":"1","author":"Viberti","year":"1982","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.007_bib19","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1530\/acta.0.1000550","article-title":"Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin excretion","volume":"100","author":"Parving","year":"1982","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1053\/j.ackd.2014.01.007_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJM198407123110204","article-title":"Predicting diabetic nephropathy in insulin-dependent diabetic patients","volume":"311","author":"Mogensen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.007_bib21","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/bmj.305.6861.1051","article-title":"Predictive value of microalbuminuria in patients with insulin dependent diabetes of long duration","volume":"305","author":"Forsblom","year":"1992","journal-title":"BMJ"},{"key":"10.1053\/j.ackd.2014.01.007_bib22","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2337\/diabetes.49.9.1399","article-title":"The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?","volume":"49","author":"Caramori","year":"2000","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1681\/ASN.2005101075","article-title":"Enhancing the predictive value of urinary albumin for diabetic nephropathy","volume":"17","author":"Caramori","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib24","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa021835","article-title":"Regression of microalbuminuria in type 1 diabetes","volume":"348","author":"Perkins","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.007_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.38070.450891.FE","article-title":"Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study","volume":"328","author":"Hovind","year":"2004","journal-title":"BMJ"},{"key":"10.1053\/j.ackd.2014.01.007_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mcna.2012.10.008","article-title":"Clinical manifestations and natural history of diabetic kidney disease","volume":"97","author":"Ritz","year":"2013","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.ackd.2014.01.007_bib27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2337\/diacare.27.1.195","article-title":"Nonalbuminuric renal insufficiency in type 2 diabetes","volume":"1","author":"Maclsaac","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2014.01.007_bib28","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1681\/ASN.2007080837","article-title":"Acute kidney injury increases risk of ESRD among elderly","volume":"20","author":"Ishani","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.00220605","article-title":"Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey","volume":"1","author":"Liangos","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00005792-195912000-00001","article-title":"Diabetic nephropathy: a clinical and pathologic study based on renal biopsies","volume":"38","author":"Gellman","year":"1959","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.ackd.2014.01.007_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/BF01235631","article-title":"Morphometric studies of the peripheral glomerular basement membrane in early juvenile diabetes I. Development of initial basement membrane thickening","volume":"8","author":"\u00d8sterby","year":"1972","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2014.01.007_bib32","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1172\/JCI111523","article-title":"Structural functional relationships in diabetic nephropathy","volume":"74","author":"Mauer","year":"1984","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.007_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.semnephrol.2012.07.003","article-title":"Morphologic features of declining renal function in type 1 diabetes","volume":"32","author":"Najafian","year":"2012","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib34","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00125-008-1051-7","article-title":"The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007","volume":"51","author":"Fioretto","year":"2008","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2014.01.007_bib35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ki.1992.118","article-title":"Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients","volume":"41","author":"Parving","year":"1992","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.007_bib36","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1681\/ASN.V381458","article-title":"Heterogeneous nature of\u00a0renal lesions in type II diabetes","volume":"3","author":"Gambara","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib37","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.vph.2013.01.001","article-title":"Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update","volume":"58","author":"Arora","year":"2013","journal-title":"Vascul Pharmacol"},{"key":"10.1053\/j.ackd.2014.01.007_bib38","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S2211-9477(12)70005-5","article-title":"Pathophysiology of diabetic nephropathy","volume":"1","author":"Vinod","year":"2012","journal-title":"Clin Queries Nephrology"},{"key":"10.1053\/j.ackd.2014.01.007_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbrc.2013.02.120","article-title":"Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy","volume":"433","author":"Sun","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.ackd.2014.01.007_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.ki.5000011","article-title":"Renin increases mesangial cell transforming growth factor-bold italic beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms","volume":"9","author":"Huang","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.007_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1440-1681.2009.05292.x","article-title":"(Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation","volume":"37","author":"Matavelli","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1053\/j.ackd.2014.01.007_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1523-1755.2004.00362.x","article-title":"Activation of a local tissue angiotensin system in podocytes by mechanical strain","volume":"65","author":"Durvasula","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.007_bib43","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1046\/j.1523-1755.2002.0610s1106.x","article-title":"Effects of amino acids and glucose on mesangial cell aminopeptidase and angiotensin receptors","volume":"61","author":"Chouinard","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.007_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabet.2009.06.005","article-title":"Advanced glycation end-products: implication for the diabetic and non-diabetic nephropathies","volume":"36","author":"Daroux","year":"2010","journal-title":"Diabetes Metab"},{"key":"10.1053\/j.ackd.2014.01.007_bib45","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1053\/j.ajkd.2009.11.021","article-title":"Potential new therapeutic agents for diabetic kidney disease","volume":"55","author":"Turgut","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.007_bib46","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.V971213","article-title":"In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation","volume":"9","author":"Abbate","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib47","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2337\/db06-0891","article-title":"Deletion of protein kinase C-beta isoform in\u00a0vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model","volume":"56","author":"Meierm","year":"2007","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib48","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.2337\/db06-0895","article-title":"Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-null mice","volume":"55","author":"Ohshiro","year":"2006","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib49","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2337\/diabetes.53.11.2921","article-title":"Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway","volume":"53","author":"Thallas-Bonke","year":"2004","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib50","doi-asserted-by":"crossref","first-page":"11047","DOI":"10.1073\/pnas.93.20.11047","article-title":"Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins","volume":"93","author":"Li","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2014.01.007_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2337\/diabetes.49.1.87","article-title":"Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C","volume":"49","author":"Osicka","year":"2000","journal-title":"Diabetes"},{"issue":"106","key":"10.1053\/j.ackd.2014.01.007_bib52","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/sj.ki.5002386","article-title":"The role of protein kinase C activation in diabetic nephropathy","author":"Noh","year":"2007","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ackd.2014.01.007_bib53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2337\/db07-1119","article-title":"Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway","volume":"57","author":"Thallas-Bonke","year":"2008","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib54","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coi.2003.12.001","article-title":"NADPH oxidase","volume":"16","author":"Babior","year":"2004","journal-title":"Curr Opin Immunol"},{"key":"10.1053\/j.ackd.2014.01.007_bib55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1053\/j.ackd.2005.01.001","article-title":"Role of oxidative stress in diabetic nephropathy","volume":"12","author":"Vasavada","year":"2005","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.007_bib56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0014-5793(00)02001-9","article-title":"Generation of superoxide from nitric oxide synthase","volume":"481","author":"Vasquez-Vivar","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1053\/j.ackd.2014.01.007_bib57","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1053\/j.ackd.2014.01.007_bib58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/0264-6021:3420231","article-title":"Role of the Janus kinase (JAK)\/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49 F cells","volume":"342","author":"Huang","year":"1999","journal-title":"Biochem J"},{"key":"10.1053\/j.ackd.2014.01.007_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/ki.2010.158","article-title":"JAK\/STAT signaling in renal diseases","volume":"78","author":"Chuang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.007_bib60","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db11-1667","article-title":"Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli","volume":"62","author":"Hodgin","year":"2013","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib61","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2337\/db08-1328","article-title":"Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy","volume":"58","author":"Berthier","year":"2009","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib62","doi-asserted-by":"crossref","first-page":"F762","DOI":"10.1152\/ajprenal.00181.2005","article-title":"Role of the JAK-STAT signaling pathway in diabetic nephropathy","volume":"290","author":"Marrero","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ackd.2014.01.007_bib63","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1146\/annurev.pharmtox.47.120505.105134","article-title":"Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease","volume":"47","author":"Schneider","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1053\/j.ackd.2014.01.007_bib64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MNH.0b013e32834dde48","article-title":"The endothelin system and endothelin receptor antagonists","volume":"21","author":"Jandeleit-Dahm","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2014.01.007_bib65","doi-asserted-by":"crossref","first-page":"F1274","DOI":"10.1152\/ajprenal.00190.2006","article-title":"Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention","volume":"291","author":"Ge","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1053\/j.ackd.2014.01.007_bib66","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2005121256","article-title":"The endothelin system and its antagonism in chronic kidney disease","volume":"17","author":"Dhaun","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib67","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nri1184","article-title":"Signaling pathways of the TNF superfamily: a double edged sward","volume":"3","author":"Aggarwal","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.ackd.2014.01.007_bib68","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.2011060627","article-title":"Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes","volume":"23","author":"Niewczas","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib69","doi-asserted-by":"crossref","first-page":"10L","DOI":"10.1016\/j.amjcard.2008.09.068","article-title":"Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection","volume":"102","author":"Brown","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ackd.2014.01.007_bib70","doi-asserted-by":"crossref","first-page":"F1622","DOI":"10.1152\/ajprenal.00078.2009","article-title":"Oxidative stress-induced JNK activation contributes to proinflammatory phenotype of aging diabetic mesangial cells","volume":"297","author":"Wu","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.007_bib71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000075627","article-title":"ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy","volume":"24","author":"Bolton","year":"2004","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.007_bib72","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1053\/j.ackd.2005.01.011","article-title":"The next generation of diabetic nephropathy therapies: an update","volume":"12","author":"Williams","year":"2005","journal-title":"Adv Chronic Kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.007_bib73","doi-asserted-by":"crossref","first-page":"F301","DOI":"10.1152\/ajprenal.00607.2010","article-title":"Recent insights into diabetic renal injury from the db\/db mouse model of type 2 diabetic nephropathy","volume":"300","author":"Tesch","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ackd.2014.01.007_bib74","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4236\/ojneph.2012.22002","article-title":"Therapeutic modalities in diabetic nephropathy: future approaches","volume":"2","author":"Reeves","year":"2012","journal-title":"Open J Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.007_bib75","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s004280100444","article-title":"Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients","volume":"439","author":"Kasajima","year":"2001","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1053\/j.ackd.2014.01.007_bib76","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/diab.38.10.1258","article-title":"Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors","volume":"38","author":"Tilton","year":"1989","journal-title":"Diabetes"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.007_bib77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1056-8727(01)00160-X","article-title":"Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in type 2 diabetic patients","volume":"15","author":"Iso","year":"2001","journal-title":"J Diabetes Complications"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.007_bib78","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1159\/000045187","article-title":"Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion","volume":"80","author":"McAuliffe","year":"1998","journal-title":"Nephron"},{"key":"10.1053\/j.ackd.2014.01.007_bib79","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.007_bib80","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in the type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.007_bib81","unstructured":"Reata web site, accessed December 18,\u00a02013."},{"issue":"304","key":"10.1053\/j.ackd.2014.01.007_bib82","doi-asserted-by":"crossref","first-page":"F808","DOI":"10.1152\/ajprenal.00376.2012","article-title":"Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects","volume":"15","author":"Zoja","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ackd.2014.01.007_bib83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1479-5876-10-213","article-title":"A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition","volume":"10","author":"Masola","year":"2012","journal-title":"J Transl Med"},{"issue":"7","key":"10.1053\/j.ackd.2014.01.007_bib84","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.2337\/diabetes.54.7.2172","article-title":"Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic patients","volume":"54","author":"Maxhimer","year":"2005","journal-title":"Diabetes"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.007_bib85","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1097\/01.ASN.0000014254.87188.E5","article-title":"Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial","volume":"13","author":"Gambaro","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib86","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1053\/j.ajkd.2011.06.020","article-title":"Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial","volume":"5","author":"Lewis","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.007_bib87","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1681\/ASN.2011040378","article-title":"Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy","volume":"23","author":"Packham","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib88","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial","volume":"376","author":"De Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.007_bib89","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib90","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib91","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.007_bib92","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET Study): a multicenter, randomised, double blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2014.01.007_bib93","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2014.01.007_bib94","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskerin for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ackd.2014.01.007_bib95","first-page":"CD008176","article-title":"Antioxidants for chronic kidney disease","author":"Venkataramna","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ackd.2014.01.007_bib96","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.272.5262.728","article-title":"Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor","volume":"272","author":"Ischii","year":"1996","journal-title":"Science"},{"issue":"11","key":"10.1053\/j.ackd.2014.01.007_bib97","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2014.01.007_bib98","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.diabres.2008.09.041","article-title":"Protein Kinase C-\u03b2 inhibition for diabetic kidney disease","volume":"82","author":"Tuttle","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1053\/j.ackd.2014.01.007_bib99","unstructured":"ClinicalTrials.gov: A service of the U.S. National Institutes of Health. http:\/\/clinicaltrials.gov\/. Accessed December 30,\u00a02013."},{"issue":"4","key":"10.1053\/j.ackd.2014.01.007_bib100","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2337\/db12-0534","article-title":"Dual inhibition of classical protein kinase C-\u03b1 and protein kinase C-\u03b2 isoforms protects against experimental murine diabetic nephropathy","volume":"62","author":"Menne","year":"2013","journal-title":"Diabetes"},{"issue":"4","key":"10.1053\/j.ackd.2014.01.007_bib101","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2337\/db12-1666","article-title":"Tandem inhibition of PKC in diabetic nephropathy: it takes two to tango?","volume":"62","author":"Thallas-Bonke","year":"2013","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2014.01.007_bib102","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1074\/jbc.M109935200","article-title":"A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation","volume":"277","author":"Voziyan","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ackd.2014.01.007_bib103","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.007_bib104","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib105","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2008090931","article-title":"Pirfenidone is renoprotective in diabetic kidney disease","volume":"20","author":"RamachandraRao","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib106","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.01050207","article-title":"Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis","volume":"2","author":"Cho","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib107","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1681\/ASN.2010101049","article-title":"Pirfenidone for diabetic nephropathy","volume":"22","author":"Sharma","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib108","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonz\u00e1lez","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib109","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1007\/s00125-005-0006-5","article-title":"Glomerular expression of thrombospondin-1, TGF-beta and CTGF at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli","volume":"48","author":"Wahab","year":"2005","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2014.01.007_bib110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/ndt\/gfh570","article-title":"Imbalance of growth factor signalling in diabetic kidney disease: is CTGF (CCN2) the perfect intervention point?","volume":"20","author":"van Nieuwenhoven","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2014.01.007_bib111","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ki.5000054","article-title":"Renal fibrosis: new insights into the pathogenesis and therapeutics","volume":"69","author":"Liu","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.007_bib112","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/diacare.26.9.2632","article-title":"Urinary CTGF excretion in patients with type 1 diabetes and nephropathy","volume":"26","author":"Gilbert","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2014.01.007_bib113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/diacare.29.01.06.dc05-1670","article-title":"Urinary CTGF excretion correlates with clinical markers of renal disease in a large population of type I diabetic patients with diabetic nephropathy","volume":"29","author":"Nguyen","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2014.01.007_bib114","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.2337\/diacare.27.5.1164","article-title":"CTGF is increased in plasma of type 1 diabetic patients with nephropathy","volume":"27","author":"Roestenberg","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2014.01.007_bib115","first-page":"249","article-title":"CTGF N fragment: a maker of progressive diabetic nephropathy","volume":"13","author":"Jaffa","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib116","first-page":"199A","article-title":"Anti-CTGF therapy with FG-3019 prevents diabetes-induced cardiovascular complications in streptozotocin treated rats [Abstract]","volume":"16","author":"Langsetmo","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib117","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.2215\/CJN.09321209","article-title":"Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria","volume":"5","author":"Adler","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.007_bib118","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/ndt\/gfh127","article-title":"Pentoxifylline suppresses renal tumor necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats","volume":"19","author":"Chen","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.007_bib119","first-page":"CD006800","article-title":"Pentoxifylline for diabetic kidney disease","author":"Shan","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ackd.2014.01.007_bib120","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jdiacomp.2010.09.003","article-title":"Pentoxifylline for renoprotection in diabetic nephropathy. Rationale and basal results","volume":"25","author":"Navarro-Gonz\u00e1lez","year":"2011","journal-title":"J Diabetes Complications"},{"key":"10.1053\/j.ackd.2014.01.007_bib121","unstructured":"Effect of Pentoxifylline on Proteinuria in Korean Type 2 Diabetic Patients Study. Clinical Trial NCT01382303. Available at: www.clinicaltrials.gov. Accessed December 30,\u00a02013."},{"issue":"2","key":"10.1053\/j.ackd.2014.01.007_bib122","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cytogfr.2009.02.005","article-title":"Tumor necrosis factor-alpha as a therapeutic target for diabetic nephropathy","volume":"20","author":"Navarro-Gonz\u00e1lez","year":"2009","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1053\/j.ackd.2014.01.007_bib123","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1053\/j.ackd.2014.01.007_bib124","unstructured":"AbbVie. Available at: www.abbvie.com. Accessed October 10, 2013."},{"key":"10.1053\/j.ackd.2014.01.007_bib125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1517\/13543784.14.3.279","article-title":"Agents in development for the treatment of diabetic nephropathy","volume":"14","author":"Fukami","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.007_bib126","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1053\/j.ajkd.2006.11.019","article-title":"Excerpts from the United States Renal Data 2006 Annual Data Report","volume":"49","author":"Collins","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.007_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med Clin North Am"},{"key":"10.1053\/j.ackd.2014.01.007_bib128","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.2215\/CJN.00730111","article-title":"Chronic kidney awareness among individuals with clinical markers of kidney dysfunction","volume":"6","author":"Tout","year":"2011","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154855951400010X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154855951400010X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T10:52:14Z","timestamp":1648464734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154855951400010X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":128,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S154855951400010X"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2014.01.007","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}